- Contact Us
- Discover CoENZYME Q10
Jump to studies about CoQ10 and:
“Serum coenzyme Q10 levels as a predictor of dementia in a Japanese general population.”
Atherosclerosis. 2014; 237:433-434.
While no studies prior to this one have found a significant difference in CoQ10 levels of patients who have dementia and those who do not, this study discovered an association between lower CoQ10 levels and a lower ratio of CoQ10/total cholesterol and future dementia risk. It is possible that low CoQ10 levels could be regarded as a predictor of dementia development rather than as a biomarker of its presence. The association may be connected with the increased oxidative stress seen in the brains of Alzheimer’s patients and CoQ10’s antioxidant activities in cellular mitochondria and lipid membranes. Though findings have been conflicting, some studies have found that Alzheimer’s patients also demonstrate lower vitamin C and E levels. CoQ10 is capable of enhancing the levels of other antioxidant nutrients. More research will be required to discover CoQ10’s relationship to dementia development and its exact method of action.
FULL STUDY: Serum coenzyme Q10 levels as a predictor of dementia in a Japanese general population
Fotino AD, Thompson-Paul AM, Bazzano LA.
“Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis.”
American Journal of Clinical Nutrition. 2013 Feb; 97(2): 268–275.
Of 120 potentially relevant studies, 13 were selected for a meta-analysis to determine CoQ10 effects on congestive heart failure (CHF). The analysis focused on primary indicators of CHF, namely ejection fraction (EF) and New York Heart Association (NYHA) functional classification in CHF patients. The meta analysis found significant improvement in EF for subjects receiving CoQ10 supplementation compared to control groups. It also saw improvement in NYHA for CoQ10 groups, but that improvement was not statistically significant. Positive effects are likely due to CoQ10’s involvement in ATP synthesis in heart muscle.
FULL STUDY: Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis
“The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO: A Randomized Double-Blind Trial.”
Journal of the American College of Cardiology – Heart Failure. 2014: Dec;2(6):641-9.
420 cardiology patients were enrolled in this double-blind placebo-controlled trial and were assigned either CoQ10 supplementation (100 mg, three times daily) or a placebo for two years. While there were no changes in short term endpoints, there were significant differences in the supplementation and placebo groups at the end of the two-year trial. Long-term CoQ10 supplementation was found to be safe and more effective than short-term supplementation in reducing heart failure symptoms and number of major adverse cardiovascular events.
Larijani VN, et. al.
“Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: The FAITH randomized clinical trial.”
Nutrition. 2013:29; 71–75.
Understanding that high occupational stress is associated with atherosclerosis risk, this study examined the effect of two dietary supplements known to support endothelial function. 65 Los Angeles firefighters were selected for the study and randomized into treatment and placebo groups. Aged garlic extract (AGE 300 mg tablet) and CoQ10 (30 mg tablet) were administered to the treatment group. Vascular elasticity was measured by pulse-wave velocity (PWV) and endothelial function assessed by digital thermal monitoring (DTM). Measurements were taken at baseline and at one year. Quarterly visits assessed compliance. Though the sample size was small, the study found that this supplement combination significantly improved PWV and DTM results in this high-stress group.
FULL STUDY: Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function
Cooney R, et.al.
“C-Reactive Protein, Lipid-soluble Micronutrients, and Survival in Colorectal Cancer Patients.”
Cancer Epidemiol Biomarkers Prev. 2013 July; 22(7): doi:10.1158/1055-9965.EPI-13-0199.
Relying on stored plasma samples, this study followed colorectal cancer patients for a mean of 8 years, examining possible associations between CRP levels, cancer survival rates, and fat-soluble nutrient levels (including CoQ10). CoQ10 was found to be positively associated with vitamin D3, tocopherols (E), retinol, and most carotenoids. It was also inversely associated with all-cause mortality. The study suggested that low levels of vitamin A, CoQ10, and certain carotenoids were associated with higher mortality in colorectal cancer patients.
FULL STUDY: C-Reactive Protein, Lipid-soluble Micronutrients, and Survival in Colorectal Cancer Patients
Muthukumaran K et. al.
“Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson’s disease.”
BMC Neuroscience. 2014 Jan 31;15:21.
Rats exposed to a chemical that can induce Parkinson’s disease (PD) were provided with supplementation of a water-soluble CoQ10 administered orally through their drinking water. Animals that received supplementation (within the recommended intake of 12 mg/kg/day) demonstrated significant reduction in PD symptom progression. The protective effect was conveyed only as long as supplementation continued. Symptom progression resumed when supplementation was ceased. Researchers concluded their findings justify further research into a possible connection between CoQ10’s protective antioxidant activities and the progression of PD.
Full Article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917573
Chai W, Cooney R, et. al. 2011.
“Plasma Coenzyme Q10 Levels and Prostate Cancer Risk: The Multiethnic Cohort Study.”
Cancer, Epidemiology, Biomarkers, and Prevention. 20(4):708-710.
This study examined CoQ10 levels in 307 men, from blood samples drawn prior to prostate cancer diagnosis. Mean time between blood draw and diagnosis was 1.9 years. The study found a slight inverse relationship between CoQ10 levels and prostate cancer risk, but it was not statistically significant. The sample group was large and diverse, but the study was limited by the short follow-up time from blood draw to cancer diagnosis (av. 1.9 years). There were also only 54 advanced cases. These initial findings warrant more research to examine the relationship between CoQ10 and prostate cancer risk.
FULL STUDY: Plasma Coenzyme Q10 Levels and Prostate Cancer Risk
Lee BJ, et. al.
“Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial.”
Nutrition Journal. 2013; 12:142.
Subjects of this study were individuals with diagnosed coronary artery disease who were being treated with statin therapy and had been taking statins for at least one month. The subjects (n=51) were assigned to either a placebo or CoQ10 300 mg group for 12 weeks. CoQ10 levels along with vitamin E, antioxidant enzymes, CRP, and other immune system markers were measured in the 42 subjects who completed the study. Subjects in the CoQ10 group had significantly higher CoQ10 levels and significantly higher levels of vitamin E and antioxidant enzyme levels at week 12. The CoQ10 group also demonstrated lower CRP (inflammation marker) levels. Findings confirm the ability of supplemented CoQ10 to maintain CoQ10 levels, heighten the activity of other antioxidants, and reduce inflammation during statin therapy.
FULL STUDY: http://www.nutritionj.com/content/12/1/142
Skarlovnik A, et al.
“Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study.”
Medical Science Monitor. 2014 Nov 6;20:2183-8.
Responding to questions about the consistency of CoQ10 supplementation in addressing statin-associated myopathy, this study utilized only a specific group of patients who were taking statins and had reported mild-to-moderate muscular pain. In this double-blind, placebo-controlled, randomized study, 50 subjects were divided into 2 groups. 25 received CoQ10 supplementation (50 mg twice daily) for one month; 25 received a placebo.
Pain Severity Scores and Pain Interference Scores were reduced by 33% and 40% respectively in the CoQ10 supplementation group, while no changes were seen in the placebo group. Researchers concluded that CoQ10 supplementation (50 mg twice daily) can successfully reduce muscle pain in patients taking statins, after only one month.
Full Article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226312